Tulisokibart

The Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market was valued at approximately $750 million in 2022 and is expected to grow significantly through 2034, driven by increasing disease prevalence and emerging therapies.

Teva and Sanofi's duvakitug met primary endpoints in a Phase 2b trial for ulcerative colitis (UC) and Crohn's disease (CD).

A Phase 2 trial of tulisokibart, an anti-TL1A monoclonal antibody, demonstrated superior efficacy compared to placebo in inducing clinical remission in patients with moderate to severe ulcerative colitis.